Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer

Dimakakos, Evangelos; Livanios, Konstantinos; Vathiotis, Ioannis; Gomatou, Georgia; Gkiozos, Ioannis; Κοττέας, Ηλίας; Kainis, Elias; Syrigos, Konstantinos

doi:10.21873/anticanres.14911

Cited by 4 publications

(2 citation statements)

References 25 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for VTE in patients with cancer are mainly cancer sites, metastasis stage, hospitalisation, central venous catheters, surgery, systemic medical anticancer therapies, history of previous VTE, cardiovascular diseases, obesity, immobility, thrombocytosis, leucocytosis and high D-dimer level 4. For lung cancer, previous studies showed that risk factors that are associated with the development of VTE mainly comprise but not limited to metastatic disease, adenocarcinoma subtype, chemotherapy administration, emergency admission, weight, performance status (PS), C-reactive protein (CRP), prothrombin time (PT), D-dimer, body mass index (BMI), major vessel infiltration, tyrosine kinase inhibitor (TKI) genetic mutation, surgery, immune checkpoint inhibitor (ICI) therapy and central venous catheter (CVC) 9 13 17 19–24. Among the aforementioned factors, TKI genetic mutations, surgery and ICI therapy are the most noteworthy ones in recent years.…”

Section: Assessmentmentioning

confidence: 99%

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review

Xiong

Guo

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is common and life-threatening in patients with lung cancer. Management of VTE is critical for patients with lung cancer. Risk assessment, thromboprophylaxis and treatment of VTE constitute the core issues of VTE management in patients with lung cancer. Although its overall principles should follow recommendations in authoritative guidelines, VTE management in patients with lung cancer may be slightly special in some specific aspects. Despite the extensive validation of Khorana score for patients with all cancer types, its value in VTE risk assessment of patients with lung cancer is controversial. It is important to determine the VTE risk assessment score that can accurately and specifically assess the VTE risk of patients with lung cancer. Clinical practice patterns of thromboprophylaxis may vary by cancer types, since different sites of cancer may have different levels of VTE risk. To understand the thromboprophylaxis specific for lung cancer is of vital importance for patients with lung cancer. Although it is essential to comply with authoritative guidelines, the duration and timing of initiation of thromboprophylaxis in surgical patients with lung cancer may need further study. Taken together, the purpose of this review is to provide an overview of state-of-the-art VTE stewardship specific for patients with lung cancer.

show abstract

Section: Assessmentmentioning

confidence: 99%

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review

Xiong

Guo

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

show abstract

“…Apart from cancer-related risk factors, patient-related and therapy-related risk factors predisposing to CAT have been identified. More specifically, patient-related factors include age (≥65 years), female sex, black race, comorbid conditions (obesity, heart or respiratory disease, renal failure, acute infection, cardiovascular risk factors or disease), immobility, and previous history of VTE (75). Therapy-related factors include major surgery (76), central venous catheters (77), and differential risk associated with chemotherapy agents, where the highest risk is associated with cisplatin, L-asparaginase thalidomide, lenalidomide and tamoxifen (78).…”

Section: Cancer-associated Thrombosismentioning

confidence: 99%

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currently

show abstract

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

Xu,

Wu,

Ren

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe prevalence of venous thromboembolism (VTE) is high in patients with cancer and can often present as the first symptom of malignancy. Cancer-associated VTE is one of the most important risk factors contributing to cancer mortality, making its prevention and treatment critical for patients with lung cancer.MethodsWe systematically searched for observational studies that estimated the prevalence of VTE in patients with lung cancer. A comprehensive search of electronic databases, including PubMed, EMBASE and Cochrane Library, was systematically conducted from database inception through January 21, 2022. The qualities of included studies were assessed in three domains, including patient selection, comparison, and results. Random effects meta-analyses of the prevalence of VTE in lung cancer were conducted using the metaprop procedure. Chi-square test and I2 value were used to evaluate study heterogeneity.ResultsThirty-five studies involving 742,156 patients were considered eligible for this study. The pooled prevalence of VTE among patients with lung cancer was 5% (95% CI: 0.043–0.056, P = 0.000). The regional prevalence of VTE was 7% (95% CI: 0.06–0.08; I2 = 99.2%) in North America, 8% (95% CI: 0.06–0.10; I2 = 97.6%) in Asia, 6% (95% CI: 0.04–0.09; I2 = 95.9%) in Europe and 11% (95% CI: 0.07–0.15) in Australasia.ConclusionsThe prevalence of lung cancer-related VTE is high and region-specific. These results of this review emphasize the importance of understanding the incidence of lung cancer-related VTE and provide argue for VTE screening of patients with lung cancer.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier PROSPERO (CRD42022306400).

show abstract

Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer

Cited by 4 publications

References 25 publications

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About